Hereditary leiomyomatosis and renal cell carcinoma (HLRCC), caused by germline FH mutations, is a rare autosomal dominant syndrome. This report details a 42-year-old woman with aggressive FH-deficient renal cell carcinoma (RCC) and multiple uterine leiomyomas. Radical nephrectomy and subsequent hysterectomy confirmed FH-deficient tumors via immunohistochemistry and genetic testing (FH c.1240A>G, p. Lys414Glu). Despite adjuvant immunotherapy and targeted therapy, rapid bone metastasis occurred postoperatively. This case highlights the aggressive nature of HLRCC-associated RCC, underscores challenges in therapeutic management, and emphasizes the necessity of early genetic testing and multidisciplinary surveillance to improve outcomes.

目的 探讨芳基烃受体核转位因子样蛋白2(ARNTL2)在子宫内膜癌中的表达、作用及其可能的信号通路.方法 采用免疫组织化学SP法、RT-PCR和Western blotting实验检测子宫内膜癌及正常内膜组织中ARNTL2的表达;小干扰RNA(Si-ARNTL2)敲低ARNTL2的表达,CCK-8实验检测细胞增殖能力,划痕愈伤实验和小室穿透实验(Transwell)检测细胞迁移和侵袭能力;Western blotting检测细胞上皮间质转化指标:N-钙黏蛋白(N-cad)、E-钙黏蛋白(E-cad)、Vimentin蛋白、Snail蛋白、Slug蛋白及Wnt/β-catenin信号通路相关蛋白(Wnt蛋白、β-连环蛋白)的表达.结果 免疫组织化学、RT-PCR和Western blotting结果均显示,ARNTL2在子宫内膜癌组织中表达上调(t免疫组织化学=2.213,P=0.033;tRT-PCR=4.766,P<0.001;tWestern blotting=2.659,P=0.012);Si-ARNTL2转染可成功降低子宫内膜癌细胞系(KLE和Ishikawa)ARNTL2的表达.敲低ARNTL2后,CCK8实验结果显示,两种细胞的吸光度值下降(P均<0.05);划痕愈伤实验结果显示,两种细胞的划痕愈合率下降(P均<0.001);Transwell侵袭及迁移实验结果均显示,两种细胞穿膜细胞数减少(P均<0.01);Western blotting实验结果显示,两细胞系E-cad表达上升(P均<0.05),N-cad、Vimentin、Snail、Slug蛋白表达下降(P均<0.05),两细胞Wnt、β-catenin蛋白的表达均下降(P均<0.05).结论 ARNTL2在子宫内膜癌组织中的表达升高,降低子宫内膜癌细胞中ARNTL2的表达可抑制子宫内膜癌的增殖和转移,其可能通过Wnt/β-catenin通路发挥作用.

RESEARCH QUESTION:Is the singleton live birth rate superior for vitrified-warmed versus fresh embryo transfer in women with adenomyosis? DESIGN:This cohort study retrospectively analysed data from the Reproductive Hospital Affiliated to Shandong University between January 2013 and December 2018. A total of 612 women diagnosed with adenomyosis, with 322 fresh embryo transfer cycles and 290 vitrified-warmed embryo transfer cycles, were included in this study. The primary outcome was singleton live birth. Outcomes were adjusted using multivariable logistic regression analysis. RESULTS:Vitrified-warmed embryo transfer was associated with a higher rate of singleton live birth than fresh embryo transfer (25.9% versus 17.4%; P = 0.011). Although there was a trend towards a lower miscarriage rate after vitrified-warmed embryo transfer, the difference did not reach statistical significance (31.3% versus 40.6%; P = 0.111). The clinical pregnancy rate was comparable in the two groups (44.1% versus 44.4%; P = 0.946). Vitrified-warmed embryo transfer also resulted in a lower risk of preterm birth than fresh embryo transfer (7.0% versus 17.5%; P = 0.010). CONCLUSIONS:Vitrified-warmed embryo transfer may be associated with better pregnancy outcomes than fresh embryo transfer among women with adenomyosis. It seems that vitrified-warmed embryo transfer is more appropriate for specific populations.

ObjectiveTo investigate the adjuvant efficacy of metformin treatment to achieve pathological complete response (CR) in patients with endometrial complex hyperplasia (CH) and complex atypical hyperplasia (CAH), and secondarily, to evaluate their pregnancy outcomes after following assisted reproductive technology (ART).Study DesignThis prospective cohort study analyzed 219 patients diagnosed with infertility and CH/CAH from January 2016 to December 2020. Among these patients, 138 were assigned to the control group (progesterone alone) and 81 were assigned to the study group (progesterone+metformin). After 8/12 weeks of therapy, the treatment responses were assessed by histological examination of curettage specimens obtained by hysteroscopy. Once the pathological results indicated CR, the patients were able to receive ART. The ART treatment and follow-up data of these patients were collected and analyzed.Results116 patients in the control group achieved CR, compared with 76 patients in the study group. The CR rate in the control group was significantly lower than that in the study group (P=0.034). We then divided the patients into subgroups to compare the treatment responses. In the subgroup analyses, patients with body mass index (BMI) ≥25 kg/m2 and patients with polycystic ovarian syndrome (PCOS) had higher CR rates in the metformin group compared with the control group (P=0.015, P=0.028 respectively). Subsequently, 68 patients in the control group and 47 patients in the study group received an ART cycle. We examined the pregnancy indications and found no significant differences in the clinical pregnancy rate and live birth rate between the two groups (P>0.05).ConclusionRegression of CH/CAH may be improved by progesterone+metformin compared with progesterone alone. The effect was particularly pronounced in patients with BMI ≥25 kg/m2 and patients with PCOS. Metformin had no obvious effect on subsequent ART outcomes. The trial is registered on the publicly accessible website:Clinical Trial Registrationhttp://www.chictr.org.cn/showproj.aspx?proj=15372, identifier ChiCTR-ONR-16009078.

Objectives: Melatonin (MLT) shows antitumor effects in various tumor types, including endometrial carcinoma. However, the molecular mechanism involved is unclear. In the current study, we investigated the effect of MLT on the estrogen-induced epithelial-mesenchymal transition (EMT) in endometrial adenocarcinoma cells and explored the pathway that might be involved. Design: Laboratory study was via cultured endometrial cancer cells. Design refers only to in vitro experiments. Methods: In cell culture experiments, cell growth was examined using CCK-8 assays. The expression of Numb and EMT markers in Ishikawa cells was examined using Western blot analysis and real-time PCR. Cell invasion was examined using transwell assays. Cell migration was examined using wound-healing assays and transwell assays. Using immunohistochemistry analysis, the expression of Numb in human endometrial cancers was examined. Results: In immunohistochemistry experiments, we found that 15.2% of atypical endometrial hyperplasia and 15.6% of endometrial carcinoma did not express Numb. In cell culture experiments, MLT inhibited cell proliferation, invasion, and migration induced by 17β-estradiol (E2) in endometrial cancer cells. MLT decreased the expression of vimentin and Slug and increased the expression of Numb and E-cadherin in Ishikawa cells. Numb knockdown in cancer cells significantly increased cell proliferation, invasion, and migration. Limitations: No animal experiments were performed. Conclusions: MLT blocked E2-induced cell growth and EMT in endometrial cancer cells via upregulating Numb expression.

目的:探讨NLR家族含CARD结构蛋白3(NLRC3)在子宫内膜癌组织中的表达情况及其对子宫内膜癌细胞系生物学行为的影响.方法:采用GEPIA数据库分析子宫内膜癌患者NLRC3表达水平及其与无病生存率的关系.免疫组化、Western blot法检测NLRC3在子宫内膜样癌组织、癌旁组织、对照组子宫内膜组织中的表达.Ishikawa(ISK)、KLE细胞转染过表达NLRC3慢病毒,细胞平板克隆、划痕愈伤实验、Transwell迁移及侵袭实验检测NLRC3对体外细胞增殖、迁移、侵袭的影响.Western blot实验检测过表达NLRC3对上皮间质转化(EMT)的影响.构建裸鼠皮下成瘤模型,检测过表达NL-RC3对肿瘤生长的影响.结果:GEPIA数据库分析显示,NLRC3在子宫内膜癌组织中低表达,较高水平NLRC3与较好的无病生存率有关(P<0.05).免疫组化、Western blot实验结果与数据库分析一致,NLRC3在子宫内膜样癌组织中的表达水平低于正常子宫内膜组织、配对癌旁组织(P<0.05),NLRC3表达随肿瘤病理分化程度降低而逐渐降低.ISK、KLE细胞过表达NLRC3后,克隆形成率下降(P均<0.05),细胞划痕愈合率下降(PISK<0.01,PKLE<0.0001),细胞穿膜数减少(P均<0.01).Western blot检测EMT相关指标(E-cadherin、N-cadherin、Vimentin),KLE细胞中N-cadherin、Vimentin表达水平下降(P<0.05).裸鼠皮下成瘤模型表明,肿瘤重量降低(P<0.05).结论:NLRC3在子宫内膜样癌组织中低表达,可抑制子宫内膜癌细胞系的增殖、迁移、侵袭、EMT等恶性行为.

Abstract Aim Study the effect of low-dose aspirin on the endometrial receptivity in endometriosis rat models. Materials and methods This study is to explore the expressions of progesterone receptor and LIF among three groups of endometriosis rat models: control group (n = 12), EMs group (n = 15), and aspirin group (n = 17). The expressions of progesterone receptor (PR), PRA, PRB, and leukemia inhibitory factor receptor (LIFR) in eutopic endometrium were determined using immunohistochemistry technology, western blot, and qRT-PCR. The levels of LIF in eutopic endometrium and serum were detected by western blot, qRT-PCR, and ELISA. Results The expressions of PR, PRA, and PRB protein were significantly increased in the eutopic endometrium after low-dose aspirin treatment, and the level of PRB mRNA was also increased while the ratio of PRA/PRB mRNA was decreased in the eutopic endometrium. The levels of LIF in eutopic endometrium and serum were increased compared with the untreated endometriosis rats. However, the expression of LIFR was not statistically different among the three groups. Conclusions The results suggest that the low-dose aspirin treatment could downregulate progesterone resistance and increase the expression of LIF of endometriosis rats during the implantation window, which could improve endometrial receptivity and enhance the pregnant rate of endometriosis. It may provide a potential treatment method for endometriosis-related infertility.

Background: The presence of ectopic functional endometrial glands and stroma in the myometrium of the uterine cavity is considered as adenomyosis. Various inflammatory, vascular and mechanical factors are involved in the symptoms and evolution of this pathology. Lymphocyte-activation gene 3 (Lag-3) is an immune inhibitory receptor and fibrinogen-like protein 1 (Fgl-1) is a major functional ligand of Lag-3. The binding of Lag-3 and Fgl-1 leads to inhibition of T-cell immunity, which is an important target of immunotherapy. The objective of this study was to evaluate the expression of Lag-3 and Fgl-1 in normal endometrium and adenomyosis. Methods: The expression of the Lag-3 and Fgl-1 in normal endometrium (proliferative phase: n=15; secretory phase: n=15) and adenomyotic endometrium (proliferative phase: n=15; secretory phase: n=15) were determined using immunohistochemistry and immunofluorescence analysis. Results: In normal and adnomyotic endometrium, no significant difference of Fgl-1 expression was noted between proliferative and secretory phases. Compared with normal endometrium, eutopic and ectopic endometrium of adenomyosis showed increased expression of Fgl-1. Lag-3 was almost negative in endometrial glands of normal and adenomyosis. Compared with normal endometrium, Lag-3 positive T-lymphocytes were more common in the stroma of adenomyosis. Conclusions : Our data suggest that aberrant expression of Lag-3 and Fgl-1 is present in the eutopic and ectopic endometrium of adenomyosis. We conclude that Lag-3/Fgl-1 signaling may be involved in the pathogenesis and development of adenomyosis.

The T cell immunoglobulin mucin molecule 3 (TIM-3), as a negative regulatory immune checkpoint, plays an important role in cellular immunity by binding to its ligand galectin-9 (Gal-9). Under abnormal conditions, this pathway can regulate the depletion of T cells and suppress the immune response. Abnormal expression of TIM-3 and Gal-9 has been confirmed in a variety of cancers, recurrent miscarriages, chronic infectious diseases and autoimmune diseases. More and more studies have shown that immune factors play an important role in the pathogenesis of adenomyosis. However, few studies have attempted to explore their expression in adenomyosis. The ectopic and eutopic endometrium were collected from 15 women with adenomyosis and 13 women without adenomyosis. TIM-3/Gal-9 expression in endometrial tissue was detected using immunohistochemistry, western blot analysis and real-time PCR. We observed TIM-3/Gal-9 expression in both eutopic and ectopic endometria, with elevated expression in adenomyosis. These data suggest that TIM-3/Gal-9 may be involved in the development and progression of adenomyosis.

目的 探讨米非司酮对人早孕绒毛组织中人类白细胞抗原G(HLA-G)表达的影响以及与终止妊娠之间的关系.方法 用免疫组化法和RT-PCR方法分别检测药物流产组和人工流产组绒毛组织中HLA-G的表达水平,结果用平均光密度和光度比值半定量方法进行分析.结果 ①免疫组化结果药物流产组(18例)绒毛组织中HLA-G的免疫组化结果的平均光密度为(0.286 957±0.108 249),人工流产组(15例)绒毛组织中该指标的平均光密度为(0.443 333±0.170 178),两组之间差别有统计学意义(P＜0.01);②RT-PCR结果药物流产组(18例)绒毛组织中HLA-G的平均光度度比值为(0.282 209±0.353 621),人工流产组(15例)该指标的平均光度比值为(1.112 719±0.724 514),两组之间差异有统计学意义(P＜0.01).结论 米非司酮药物可降低早孕绒毛组织中HLA-G的表达,从而抑制妊娠时母胎界面的免疫功能,破坏母体对胎儿组织的阶段性容受,可能是该药物致早孕流产的机制之一.

目的 探讨米非司酮、米索前列醇对滋养细胞TRIM22表达的影响.方法 临床病例分组如下:将40例早期妊娠患者分为胚胎停育组(A组)12例,人工流产组(B组)14例,药物流产组(C组)14例;体外培养滋养细胞HTR-8,按2×2析因设计随机分为如下4组:空白对照组(D组)、米索前列醇组(E组)、米非司酮组(F组)、米非司酮+米索前列醇组(G组).采用CCK-8法检测各组细胞的增殖能力.细胞划痕实验检测各组细胞的迁移能力.免疫组化检测TRIM22蛋白表达部位及表达强度.实时荧光定量PCR和Western blottiing检测TRIM22 mRNA及蛋白表达水平并进行半定量分析.结果 临床病例中,TRIM22主要表达在滋养细胞的细胞核;A、C两组的TRIM22蛋白和mRNA表达强度低于B组,差异有统计学意义(P<0.05),而A、C两组间差异无统计学意义(P>0.05).滋养细胞体外模型中,使用米非司酮组(F、G组)与未使用米非司酮组(D、E组)间比较,滋养细胞增殖能力和迁移能力降低,TRIM22 mRNA和蛋白表达强度降低(P<0.001);使用米索前列醇组(E、G组)与未使用米索前列醇组(D、F组)间比较,差异无统计学意义(P>0.05);米非司酮与米索前列醇间无明显交互作用(P>0.05).结论 米非司酮可能通过下调TRIM22的表达抑制了滋养细胞的增殖、迁移,米索前列醇对其作用无统计学意义影响.

This study aims to examine the expression of p53, p16, and murine double minute 2 (MDM2) protein in normal endometrium and endometriosis, in order to discuss the role of p53, p16, and MDM2 protein and apoptosis in the pathogenesis and development of endometriosis, and provide a theoretical basis for clinical diagnosis and treatment.The immunohistochemical streptavidin-biotin peroxidase method was used to detect the expression of p53, p16, and MDM2 in tissue samples obtained from 30 women with pathologically confirmed ovarian endometriosis and 29 women with pathologically confirmed normal endometrium. The relationship between p53, p16, and MDM2 expression and apoptosis was analyzed.In normal endometrium, the positive rate of p53 in the secretory phase was higher than that in the proliferative phase (P < .05). Furthermore, the positive rate of p53 in normal endometrium was higher than that in ovarian endometriosis (P < .05). There was a significant difference between normal endometrium and ovarian endometriosis.The positive rate of p16 in normal endometrium was higher than that in ovarian endometriosis (P < .05). Furthermore, there was a significant difference between normal endometrium and ovarian endometriosis. The positive rate of MDM2 in normal endometrium was lower than that in ovarian endometriosis (P < .05).In ovarian endometriosis, the expression of p53 and p16 was positively correlated with each other (r = 0.611, P < .01). However, the expression of p53 and MDM2 was negatively correlated with each other (r = -0.541, P < .01). Furthermore, the expression of p16 and MDM2 might not be relevant in the endometriosis (r = 0.404, P > .05).As important apoptosis regulatory genes, p53, p16, and MDM2 might be involved in the pathogenesis and development of endometriosis.

Endometrioid endometrial carcinoma (EEC) is the most common gynaecologic malignancy worldwide. Long non-coding RNAs have previously been demonstrated to play important roles in regulating human diseases, particularly cancer. However, the biological functions and molecular mechanisms of long non-coding RNAs in EEC have not been extensively studied. Here, we describe the discovery of Lnc-NA from the promoter of the transcription factor nuclear receptor subfamily 4 group A member 1 (NR4A1) gene. The role and function of Lnc-NA in EEC remain unknown. In this study, we used quantitative real-time polymerase chain reactions to confirm that Lnc-NA expression was down-regulated in 30 EEC cases (90%) and in EEC cell lines compared with that in the paired adjacent tissues and normal endometrial cells. In vitro experiments further demonstrated that overexpressing Lnc-NA decreased EEC cell proliferation, migration and invasion and promoted apoptosis via inactivation of the apoptosis signalling pathway. Moreover, the results show that Lnc-NA expression was positively correlated with NR4A1. Furthermore, Lnc-NA regulated NR4A1 expression and activated the apoptosis signalling pathway to inhibit tumour progression. In summary, our results demonstrate that the Lnc-NA-NR4A1 axis could be a useful tumour suppressor and a promising therapeutic target for EEC.

BACKGROUND:NUMB is an inhibitory regulator of NOTCH signaling, which is critical for the induction of epithelial-mesenchymal transition (EMT). Loss of NUMB expression is correlated with the genesis and development of multiple tumors. Recent studies reported that NUMB expression was upregulated in human ovarian cancer. However, the role of NUMB in ovarian cancer is still unclear. Here, we invested the effect of NUMB knockdown on the proliferation and EMT in ovarian cancer cells and explored the role of NUMB in the effect of cisplatin.METHODS:Two ovarian cancer cells (OVCAR-3 and SK-OV-3) were used in the experiments. The proliferation and apoptosis of ovarian cancer cells was examined using methyl thiazolyl tetrazolium (MTT) test and flow cytometry assays. The invasion and migration of ovarian cancer cells were examined using Transwell assays. The expression of EMT markers were examined using Simple Western analysis.RESULTS:NUMB knockdown inhibited cell proliferation, invasion, and migration in both ovarian cancer cells. NUMB knockdown enhanced cisplatin-induced cell growth inhibiting and apoptosis in both ovarian cancer cells. NUMB knockdown enhanced cisplatin-induced cell invasion in SK-OV-3 cells. NUMB knockdown also decreased the expression of N-cadherin and Vimentin in SK-OV-3 cells.CONCLUSIONS:NUMB acted as an oncogene in ovarian cancer and NUMB knockdown enhanced the anti-tumor role of cisplatin on ovarian carcinoma cells by inhibiting cell proliferation and EMT.

To investigate the role of long noncoding RNA taurine-upregulated gene 1 (TUG1) on ovarian cancer-induced angiogenesis and to explore possible signaling pathways. Ovarian cancer cell line SKOV3 or CAOV3 was transfected with short hairpin-TUG1 to suppress TUG1 expression. Supernatant from cultured cancer cells was used as a condition medium to incubate endothelial cell line human umbilical vein endothelial cells, whose proliferation rate was quantified by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. Migration and invasion of endothelial cells were examined by wound healing and Transwell assays, followed by in-vitro angiogenesis assay. One of the secretory factors mediating angiogenesis, leucine-rich α-2-glycoprotein-1 (LRG1), was measured in ovarian cancer cells. Signaling pathway mediating angiogenesis was further detected by western blotting. TUG1 was down-regulated in ovarian cancer cells by short hairpin RNA. Conditional medium originating from TUG1-knockdown cancer cells led to suppressed proliferation, migration, or invasion of endothelial cell line human umbilical vein endothelial cells. LRG1 expression and secretion was suppressed in ovarian cancer cells after TUG1 knockdown. Moreover, recombinant LRG1 rescued TUG1 knockdown-induced angiogenesis inhibition, and LRG1 probably mediated angiogenesis by tumor growth factor-β signaling pathway in endothelial cells. Long noncoding RNA-TUG1 mediates angiogenesis of endothelial cells by regulating LRG1 secretion from ovarian cancer cells partially through tumor growth factor-β pathway. Our results indicate the potency of TUG1 as a biomarker and therapeutic target for tumor-induced angiogenesis.

Background. Endometrial adenocarcinoma (EAC) is one of the most commonly diagnosed gynaecological malignancies among female population of the developed countries. DUSP6 is a negative regulator of ERK signaling, which is a molecular switch involved in MAPK signaling during the progress of malignancies. DUSP6 was previously found to inhibit tumorigenesis and EMT-associated properties in several cancers, however, its exact role in EAC remains unclear. Methods. The level of DUSP6, (E-cad) and (N-cad) in EAC cancerous tissues and respective adjacent non-cancerous tissues were examined by western-blot or immunohistochemistry. The cell growth, invasion and migration abilities were measured in Ishikawa 3H12 endometrial cancer cell lines with overexpressed or knock down DUSP6. Protein levels of EMT-associated markers E-cadherin, N-cadherin and Vimentin were also determined. The impacts of DUSP6 on ERK signaling was assessed by detection of ERK and p-ERK. Results. Down-regulation of DUSP6 was observed in EAC compared with the normal controls. The overexpression of DUSP6 significantly attenuated tumor cell growth, invasion, migration abilities and inhibited EMT-associated markers, while knock down of DUSP6 showed opposite trends. Overexpression of DUSP6 also down-regulated p-ERK and the knock down of DUSP6 inversely up-regulated p-ERK level. Conclusions. DUSP6 inhibited cell growth, invasion and migration abilities in Ishikawa 3H12 cells as well as attenuating EMT-associated properties. This tumor suppressive effect of DUSP6 in EAC is achieved by inhibiting ERK signaling pathway.

Primary malignant melanoma of the vagina (PMMV) is an extreme variant of melanoma, however the incidence of this disease ranks second in the female genital tract and accounts for <3% of all vaginal malignancies. The treatment outcomes and prognosis of PMMV are very poor. This study presents the diagnosis and treatment of a patient with PMMV. A 73-year-old postmenopausal Chinese woman visited our hospital due to "abnormal vaginal bleeding for 20 days" was enrolled in this study. Gynecologial examination showed dark blue cauliflower tubercle in the lower 1/3 segment of posterior and left vaginal wall. Biopsy indicated malignant melanoma of the vagina. The patient was then hospitalized in our hospital and laboratory examination confirmed the diagnosis. She received temozolomide oral chemotherapy and half a month later underwent wide local excision. After surgery, she continued temozolomide oral chemotherapy. Unfortunately, both vaginal ultrasound and CT showed a space-occupying lesion in uterus. Endometrial biopsy showed tumor metastasis. The patient refused any additional surgical interventions but only received chemotherapy. After finishing the third chemotherapy cycle, the patient was discharged and died due to cachexia. PMMV is an extremely aggressive tumor with poor prognosis and gynecologists should pay close attention to suspicious lesions associated with abnormal vaginal bleeding or mass.

PURPOSE:The aim was to investigate mifepristone effects on endometrial carcinoma and the related mechanism. METHODS:HHUA cells were treated with DMEM containing different concentrations of mifepristone. HHUA cells treated with 100 μmol/L mifepristone were named the Mifepristone group. HHUA cells co-transfected with pcDNA3.1-PI3K and pcDNA3.1-AKT overexpression vectors were treated with 100 μmol/L mifepristone and named the Mifepristone + PI3K/AKT group. mRNA expression was detected by quantitative reverse transcription PCR. Protein expression was performed by Western blot. Cell proliferation was conducted by MTT assay. Wound-healing assay was conducted. Transwell was used to detect cells migration and invasion. Apoptosis detection was performed by flow cytometry. RESULTS:Mifepristone inhibited HHUA cells proliferation in a dose-dependent manner. Compared with HHUA cells treated with 0 μmol/L mifepristone, HHUA cells treated by 50-100 μmol/L mifepristone had a lower wound-healing rate, a greater number of migrating and invasive cells (P<0.01), as well as a higher percentage of apoptotic cells and Caspase-3 expression (P<0.01). When HHUA cells were treated with 50-100 μmol/L of mifepristone, FAK, p-FAK, p-PI3K and p-AKT relative expression was all significantly lower than HHUA cells treated with 0 μmol/L of mifepristone (P<0.01). Compared with the Mifepristone group, HHUA cells of the Mifepristone + PI3K/AKT group had a lower cell growth inhibition rate and percentage of apoptotic cells (P<0.01). CONCLUSION:Mifepristone inhibited HUUA cells proliferation, migration and invasion and promoted its apoptosis by regulation of FAK and PI3K/AKT signaling pathway.